Tobacco heated products : a new challenge in tobacco control Los productos de tabaco calentado: nuevo reto en el control del tabaco
Peruga, Armando (Universidad del Desarrollo (Santiago de Chile))
Rodríguez Lozano, Francisco (European Network for Smoking and Tobacco Prevention (Bèlgica))
López Medina, María José (Institut d'Investigació Biomèdica Sant Pau)
Córdoba García, Rodrigo (Universidad de Zaragoza. Facultad de Medicina)
Nerín, Isabel (Universidad de Zaragoza. Facultad de Medicina)
Sureda, Xisca (Institut d'Investigació Biomèdica de Bellvitge)
Fernández, Esteve (Institut d'Investigació Biomèdica de Bellvitge)

Date:	2022
Abstract:	As cigarette sales decline, the tobacco industry has turned to the sale of heated tobacco products (HTP), which are on the rise. We are concerned with reports erroneously indicating that heated tobacco is associated with a lower risk of cancer and other diseases than conventional cigarettes, citing as a source the Food and Drug Administration (FDA) of the United States. The FDA has indeed authorized the sale of an HTP, but denies that this approval is an endorsement of the product or that it is safe. Philip Morris asked the FDA to approve this product as a "modified risk" tobacco product. However, the Agency denied that the risk to users' health was less than conventional cigarettes, despite emitting less amount of some toxicants. Spain and the European Union should end the regulatory privileges that HTPs have until now. We identified at least five aspects to improve: 1) compliance with the prohibition of HTPs use where smoking is prohibited; 2) control of the prohibition of advertising, promotion, and sponsorship of HTPs; 3) that HTPs carry the same type of labeling as cigarettes; 4) limit that HTPs have characteristic aromas; and 5) treat HTPs fiscally at the same level as cigarettes.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Language:	Castellà
Document:	Article ; recerca ; Versió publicada
Subject:	Tobacco ; IQOS ; Reduced exposure ; Modified risk ; Health damage ; Tobacco industry
Published in:	Gaceta sanitaria, Vol. 36 Núm. 1 (enero 2022) , p. 57-59, ISSN 1578-1283

DOI: 10.1016/j.gaceta.2020.12.033
PMID: 33563478

3 p, 158.6 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles